OpenAI Promotes ChatGPT for Health Decisions Amid Accuracy Concerns

OpenAI published a case study this week featuring a family that used ChatGPT to prepare for their son’s cancer treatment decisions, positioning the AI chatbot as a complement to physician guidance. The timing raises eyebrows given mounting evidence that AI health tools carry significant reliability problems.

The promotional piece, released March 4, describes how parents leveraged ChatGPT alongside their child’s oncology team. OpenAI frames this as responsible AI use—supplementing rather than replacing medical expertise.

But the rosy narrative collides with uncomfortable research findings. A study published in Nature Medicine examining OpenAI’s own “ChatGPT Health” product found substantial problems with accuracy, safety protocols, and racial bias in medical recommendations. That’s not a minor caveat for a tool people might use when making life-or-death decisions about cancer treatment.

The Accuracy Problem

Independent research paints a mixed picture at best. A Mass General Brigham study found ChatGPT achieved roughly 72% accuracy across medical specialties, climbing to 77% for final diagnoses. Sounds decent until you consider what’s at stake—would you board a plane with a 23% chance of the pilot making a critical error?

Healthcare AI company Atropos delivered even grimmer numbers: general-purpose large language models provide clinically relevant information just 2% to 10% of the time for physicians. The gap between “sometimes helpful” and “reliable enough for cancer decisions” remains vast.

The American Medical Association hasn’t minced words. The organization recommends against physician use of LLM-based tools for clinical decision assistance, citing accuracy concerns and absent standardized guidelines. When the AMA tells doctors to steer clear, patients should probably take note.

What ChatGPT Can’t Do

AI chatbots can’t perform physical examinations. They can’t read a patient’s body language or ask the intuitive follow-up questions that experienced oncologists develop over decades. They can hallucinate—generating confident-sounding information that’s completely fabricated.

Privacy concerns add another layer. Every symptom, every fear, every detail about a child’s cancer typed into ChatGPT becomes data that users have limited control over.

OpenAI’s case study emphasizes the family worked “alongside expert guidance from doctors.” That qualifier matters. The danger isn’t informed patients asking better questions—it’s vulnerable people in crisis potentially over-relying on a tool that gets things wrong more often than the marketing suggests.

For crypto investors watching OpenAI’s enterprise ambitions, the healthcare push signals aggressive expansion into high-stakes verticals. Whether regulators will tolerate AI companies promoting medical decision-making tools with documented accuracy problems remains an open question heading into 2026.

Image source: Shutterstock